Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients

Everolimus after surgery can improve outcomes in those with high-risk kidney cancer

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma